Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

PLYX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income grows 106.8% year over year

Q4 FY2025 net income of $1.5M (cash outflow) rose 106.8% year over year. Sequentially, it rose 4.5% from the prior quarter.

Context

  • Net income grew in size in 1 of the last 2 fiscal years.

What to watch

Whether net income reaches the consensus estimate of -$5.68M (-36.8%) for the fiscal year ending Dec 2026, a step up from the -70.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-$1.5M+4.5% QoQ
Last fiscal yearDec 2025
-$8.99M-70.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+106.8%-81.3%-188.1 pp
1 year-70.4%-36.8%+33.6 pp
3-year CAGR—+32.4%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(8.99M) USD
Year-over-year change
+70.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How PLYX compares with its peers on the latest reported figures

  • PLYX's FY2025 net income of $8.99M is the smallest of the 8 companies compared; the peer median is $75.32M.
  • Its year-over-year change of -70.4% is the lowest of 6, against a peer median of -6.4%.
PLYX Competitors Peer median
Net Income for PLYX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$246.41M -26.3%+14.4%794858.1%
CBIOCrescent Biopharma, Inc.LTM Mar 2026$162.08M +206.1%+47.5%1363.9%
JBIOJade Biosciences, Inc.LTM Mar 2026$129.61M —+35.2%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$75.32M -6.4%-12.0%266.9%
PTHSPelthos Therapeutics Inc.LTM Mar 2026$51.59M +600.9%+160.2%186.2%
KLRSKalaris Therapeutics IncLTM Mar 2026$44.1M —+41.0%—
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$34.55M -23.8%-4.9%—
PLYXPolaryx Therapeutics, Inc. Common StockFY2025$8.99M -70.4%——
Peer median (excluding PLYX) $75.32M-6.4%+35.2%815.4%

Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Intrinsic Alpha fair value

Locked

Current Price

$1.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.